Herold Advisors’s Editas Medicine EDIT Stock Holding History

Herold Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500	Closed	-$20K	–	308
2021 Q3	$20K	Buy	+500	New	+$27.4K	0.01%	515

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Herold Advisors's EDIT Position: Q4 2021 in Review

Herold Advisors sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 500 shares — an estimated $20K sold.

Herold Advisors first reported a position in EDIT in Q3 2021 and held it in 1 quarter. The position peaked at $20K in Q3 2021. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

Herold Advisors reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
Herold Advisors sold 500 Editas Medicine shares in Q4 2021, an estimated $20K.
Herold Advisors first reported a position in Editas Medicine in Q3 2021 and held it in 1 quarter.
Herold Advisors's Editas Medicine position peaked at $20K in Q3 2021.
305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Herold Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.